Humacyte (HUMA) CMO executes 45,887-share tax sell-to-cover under 10b5-1 plan

Rhea-AI Filing Summary

Humacyte, Inc.'s Chief Medical Officer, Shamik J. Parikh, reported an automated sale of 45,887 shares of common stock at an average price of $0.8967 per share.

The filing explains this was a mandatory “sell-to-cover” transaction to fund statutory tax withholding tied to vesting of restricted stock units, carried out under a Rule 10b5-1(c) trading plan and not a discretionary sale. After this tax-related sale, Parikh directly holds 272,713 shares of Humacyte common stock.

Insider Trade Summary 10b5-1

Net Seller: 45,887 shares ($41,147)

Net Sell 1 txn

Insider Parikh Shamik J

Role Chief Medical Officer

Sold 45,887 shs ($41K)

Type	Security	Shares	Price	Value
Sale	Common Stock	45,887	$0.8967	$41K

Holdings After Transaction: Common Stock — 272,713 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 45,887 shares Average sale price: $0.8967 per share Shares held after transaction: 272,713 shares

3 metrics

Shares sold 45,887 shares Automated sell-to-cover on RSU vesting

Average sale price $0.8967 per share Tax-related sale of common stock

Shares held after transaction 272,713 shares Direct holdings after tax sell-to-cover

Key Terms

restricted stock units, statutory tax withholding obligations, sell-to-cover, Rule 10b5-1(c)

4 terms

restricted stock units financial

"in connection with the vesting of restricted stock units previously granted to the Reporting Person"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

statutory tax withholding obligations financial

"to cover the statutory tax withholding obligations in connection with the vesting"

sell-to-cover financial

"to be funded by a "sell-to-cover" transaction pursuant to a plan"

Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.

Rule 10b5-1(c) regulatory

"plan ... intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parikh Shamik J

(Last) (First) (Middle)

2525 EAST NORTH CAROLINA HIGHWAY 54

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Humacyte, Inc. [ HUMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	05/18/2026		S		45,887	D	$0.8967	272,713	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of Common Stock sold under an automated program to cover the statutory tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. This sale was mandated by the Issuer's practice to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction pursuant to a plan entered into by the Reporting Person for the purchase or sale of equity securities of the Issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), and therefore does not represent a discretionary sale by the Reporting Person.

	/s/ Shamik J. Parikh by Dale A. Sander as Attorney-in-Fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Humacyte (HUMA) report for Shamik J. Parikh?

Humacyte reported that Chief Medical Officer Shamik J. Parikh sold 45,887 shares of common stock at an average price of $0.8967 per share. The shares were sold automatically to cover statutory tax withholding on vesting restricted stock units, rather than as a discretionary open-market sale.

Why did Humacyte (HUMA) CMO’s shares get sold in this Form 4 filing?

The shares were sold under an automated “sell-to-cover” arrangement to satisfy minimum statutory tax withholding obligations arising from vesting restricted stock units. The filing notes this tax-related sale followed the company’s practice and does not represent a discretionary decision to sell shares by the executive.

Was the Humacyte (HUMA) CMO’s stock sale made under a Rule 10b5-1 plan?

Yes. The filing states the sell-to-cover transaction occurred pursuant to a plan intended to meet Rule 10b5-1(c) affirmative defense conditions. Such plans pre-schedule trades, indicating this tax-motivated sale was pre-arranged rather than timed at the executive’s discretion.

How many Humacyte (HUMA) shares does the CMO hold after this transaction?

Following the tax-related sale, Chief Medical Officer Shamik J. Parikh directly holds 272,713 shares of Humacyte common stock. This figure reflects his remaining position after 45,887 shares were sold to cover statutory tax withholding on previously granted restricted stock units.

Does this Humacyte (HUMA) Form 4 indicate an open-market sale signal by management?

The filing characterizes the reported sale as a mandatory, automated sell-to-cover transaction for tax withholding on vesting restricted stock units. It specifically notes the sale does not represent a discretionary decision by the executive to sell shares in the open market.